WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, ...
Medical diagnostic firm PerkinElmer Inc said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, for about $5.25 billion in a cash-and-stock ...
PerkinElmer, Inc. (“PerkinElmer”) today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents, for approximately $5.25 ...
The team building the BioLegend Campus Project saw the light—and, initially, not in a good way. Solving the problem of LED lights potentially affecting biotechnology projects was just one of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback